Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US9782349 | IPSEN INC | Liposomes useful for drug delivery |
May, 2025
(1 year, 7 months from now) | |
US10722508 | IPSEN INC | Liposomes useful for drug delivery |
May, 2025
(1 year, 7 months from now) | |
US9724303 | IPSEN INC | Liposomes useful for drug delivery |
May, 2025
(1 year, 7 months from now) | |
US8992970 | IPSEN INC | Liposomes useful for drug delivery |
May, 2025
(1 year, 7 months from now) | |
US8329213 | IPSEN INC | Liposomes useful for drug delivery |
Jan, 2027
(3 years from now) | |
US8147867 | IPSEN INC | Liposomes useful for drug delivery |
Aug, 2028
(4 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9730891 | IPSEN INC | Liposomes useful for drug delivery |
May, 2025
(1 year, 7 months from now) | |
US8703181 | IPSEN INC | Liposomes useful for drug delivery |
May, 2025
(1 year, 7 months from now) | |
US11369597 | IPSEN INC | Methods for treating pancreatic cancer using combination therapies |
Jun, 2033
(9 years from now) | |
US9717724 | IPSEN INC | Methods for treating pancreatic cancer using combination therapies |
Jun, 2033
(9 years from now) | |
US9492442 | IPSEN INC | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
Jun, 2033
(9 years from now) | |
US9364473 | IPSEN INC | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
Jun, 2033
(9 years from now) | |
US9339497 | IPSEN INC | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
Jun, 2033
(9 years from now) | |
US9452162 | IPSEN INC | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
Jun, 2033
(9 years from now) | |
US10980795 | IPSEN INC | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
Jun, 2033
(9 years from now) | |
US10456360 | IPSEN INC | Stabilizing camptothecin pharmaceutical compositions |
Oct, 2036
(13 years from now) | |
US10993914 | IPSEN INC | Stabilizing camptothecin pharmaceutical compositions |
Oct, 2036
(13 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Oct 22, 2022 |
Drugs and Companies using IRINOTECAN HYDROCHLORIDE ingredient
Market Authorisation Date: 22 October, 2015
Treatment: Treatment of metastatic adenocarcinoma of the pancreas that has progressed on gemcitabine-based therapy, in combination with 5-fluorouracil and leucovorin; Treatment of pancreatic cancer; Treatment of...
Dosage: INJECTABLE, LIPOSOMAL;INTRAVENOUS
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic